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Abstract Progressive obliteration of the retinal microvessels
is a characteristic of diabetic retinopathy and the resultant
retinal ischemia can lead to sight-threatening macular edema,
macular ischemia and ultimately preretinal neovasculariza-
tion. Bone marrow derived endothelial progenitor cells
(EPCs) play a critical role in vascular maintenance and repair.
There is still great debate about the most appropriate markers
that define an EPC. EPCs can be isolated using cell sorting by
surface phenotype selection or in vitro cell culture. For
freshly isolated cells, EPC cell sorting is heavily dependent
on the surface markers used; EPCs can also be isolated by in
vitro propagation of heterogeneous mixtures of cells in
culture using adhesion to specific substrates and cell growth
characteristics. in vitro isolation enables consistent reproduc-
ibility and using this approach at least two distinct types of
EPCs with different angiogenic properties have been
identified from adult peripheral and umbilical cord blood;
early EPCs (eEPCs) and late outgrowth endothelial progen-
itor cells (OECs). Emerging studies demonstrate the potential
of these cells in revascularization of ischemic/injured retina
in animal models of retinal disease. Since ischemic retino-
pathies are leading causes of blindness, they are a potential
disease target for EPC-based therapy. In this chapter, we
summarize the current knowledge about EPCs and discuss
the possibility of cellular therapy for treatment of diabetic
macular ischemia and the vasodegenerative phase of diabetic
retinopathy. We also report current pharmacological options
that can be utilized to correct diabetes associated defects in
EPCs so as to enhance the therapeutic utility of these cells.
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Targeted treatment
Diabetic retinopathy, the leading cause of visual impairment
in the western world [1], will occur in the majority of type 1
diabetic patients and about 20–30% will advance to the
blinding stage of the disease. Greater than 60% of patients
with type 2 diabetes will develop retinopathy. With the
global epidemic of obesity and subsequently of type 2
diabetes, this predicament is likely to worsen. Over 360
million people are projected to suffer from diabetes and its
complications by 2030.
Hyperglycemia damages retinal microvasculature, which
results in increased permeability, blood and serum leakage
to the extra vascular space, and progressive decline in
retinal blood flow; as well as closure of the retinal
microvasculature leading to diabetic retinopathy. Diabetic
retinopathy is thought to be largely a result of diabetes-
induced retinal microvascular dysfunction and is character-
ized by capillary leakage (loss of the functional integrity of
the blood retinal barrier) or capillary closure resulting in
ischemia (the formation of acellular capillaries, with loss of
blood supply to the neural retina). Capillary leakage causes
diabetic macular edema (DME), the principal cause of
vision loss in diabetes. Capillary closure in the retina leads
to diabetic macular ischemia (DMI) and causes loss of
reading vision. Bilateral DMI causes legal blindness and
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unfortunately there is no therapy for DMI. Moreover, patients
commonly have mixed DME and DMI. In addition, the level
of damage to the microvasculature is impacted by the duration
of diabetes, the degree of blood sugar and hypertension
control, and yet to be determined patient-specific differences
in the ability to repair the damaged endothelium.
Strict metabolic and blood pressure control can lower the
risk of developing retinopathy and reducing disease
progression [1]. Newer therapies targeted at treating either
DMI or PDR include corticosteroids and anti-VEGF anti-
bodies. These approaches represent promising alternatives
to control retinopathy progression. Laser therapy, the
standard of care for DME, can be destructive to various
neurovascular layers of the retina and choroid, but results in
modest preservation of visual acuity [2, 3]. However, actual
improvement in visual acuity is uncommon. Laser is less
effective in the presence of diffuse or chronic DME and in
the presence of “mixed” DME and capillary closure [3].
When retinopathy progresses to the late stages, chronic
hypoxia/nonperfusion leads to compensatory neovasculariza-
tion which occurs in an aberrant manner mostly on the surface
of the retina. For this stage, proliferative diabetic retinopathy,
laser treatment is the most cost effective approach. However,
anti VEGF approaches similar to those used for choroidal
neovascularization show considerable promise [4].
Endothelial progenitor cells (EPCs) are now recognized
as a key cell responsible for healthy maintenance of the
vasculature, including the retina. EPCs are believed to be
derived from hematopoietic stem cells (HSCs, Fig. 1) or
alternatively the endothelium itself [6]. In the last decade, it
has been recognized that EPCs are recruited to sites
requiring repair where these cells contribute to the viability
of the vasculature [7]. Because EPCs home to sites of
damage and promote vascular integrity, they not only
mediate repair of injured tissue but lead to reperfusion of
ischemic regions within a tissue [8]. Following the
discovery of EPCs by Asahara and coworkers, EPC repair
has been observed in a wide array of processes including
myocardial ischemia/infarction, limb ischemia, wound
healing, atherosclerosis, endogenous endothelial repair,
and tumor neovascularization in mice and humans [7, 9].
This repair occurs as a series of carefully orchestrated steps:
1) EPC mobilization from bone marrow, 2) EPC circulation
to remote sites of vascular injury, 3) extravasation of EPCs
from the circulation into the area of injury and 4) finally the
assimilation with the local endothelium or paracrine support
to the local endothelium (Fig. 2). EPCs comprise 0.02% of
the total bone marrow, compared to 4% by GR1+ myeloid
cells for example, and their incorporation into vessels varies
dramatically depending on the vascular bed and the type of
injury. An engraftment efficiency of up to 95% is observed
in some vascular beds [11]. Specifically, Minami et al. have
shown that circulating EPCs engraft luminally into 15% to
29% of vessels in the transplanted human heart [12]. Bone
marrow derived endothelial cells have also been shown to
give rise to up to 16% of the neovasculature in spontaneous
tumors grown in transgenic mice [13] and they also
contribute to human tumor vessels [14].
Our group has observed very high numbers of bone
marrow derived cells contributing to both repair and
pathological neovascularization in the eye [15, 16]. We
interpreted this high percentage to be secondary to the
highly quiescent nature of the resident retinal vasculature
(typical retinal endothelial cells turnover occurs every
4 years), thus facilitating the contribution of circulating
EPCs to the newly forming vessel.
Characterization of EPCs
Characterization of the various EPC subpopulations is an area
of heated debate but there exist two main approaches to define
and/or isolate cells with endothelial characteristics and
regenerative capacity: culture selection from mononuclear
cells (either BM- or PB-derived) or the use of a set of
antibodies to various “identifying” markers of these cells.
Identification of endothelial precursors based on culture
Asahara and colleagues first characterized the endothelial
precursors in 1997 as a subset of CD34+ hematopoietic
progenitor cells [7]. They reported that peripheral blood
mononuclear cells (PB-MNCs) enriched for CD34+ cells
could differentiate into endothelial-like cells following
culture on fibronectin in the presence of growth factors.
After 7 days in culture the fraction of cells co-expressing
CD34 and VEGFR-2 increased. These cells also expressed
other endothelial markers such as CD31 (platelet endothelial
cell adhesion molecule-1, PECAM-1), tyrosine kinase with
immunoglobulin-like and EGF-like domains 2 (Tie-2) and
eNOS, incorporated acetylated low-density lipoprotein
(acLDL), bound Ulex (UEA-1) lectin and formed tube-like
structures in vitro, supporting the contention that they
possess the ability to differentiate into endothelial cells.
These findings were corroborated by Shi et al. [17].
Currently, culture selection involves the growth of PB-
MNCs in selective medium and on either fibronectin- or
collagen-coated dishes [17]. The medium typically contains a
cocktail of endothelial growth factors, such as VEGF, FGF-
2, IGF-1, PDGF-BB, as well as ascorbic acid and hydrocor-
tisone. The medium is changed regularly (usually every 24–
28 h). Culture-selected cells can be classified into two
distinct phenotypes as shown in Fig. 3 [18].
eEPCs, which are the cells originally identified by
Asahara, have been most studied to date. eEPCs are those
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mainly derived from monocytes, do not proliferate and
begin to gradually die after a few weeks in culture [18, 19].
In contrast, OECs usually begin growing >2 weeks after
isolation, eventually proliferate very rapidly, resemble
microvascular ECs (with a cobblestone morphology), and
seem to be expandable indefinitely (Fig. 4) [20, 21]. The
distinction between these two cell types is reinforced by their
expression of different markers. OECs do not express CD1a or
CD14 and have a low expression of CD45, the pan-leukocyte
marker [22]. The precise origin of the OEC is still in question
yet, Yoder’s group believes that the endothelium is the
source of this progenitor. The OEC represents one cell in a
million MNC found in the circulation and thus can only be
“identified” once it has grown out in culture [23].
Most early studies of cell therapy in the heart and limbs
employed eEPCs; thus, there is abundant evidence that
these transplanted cells can enhance revascularization [24],
although there is much debate about the mechanism of
these effects. In contrast, OECs have been minimally
studied in vivo [25]. Still their higher proliferative potential
may be important when a large supply of regenerative cells
is required. Thus, OECs may have great therapeutic utility
as a cellular therapy [8]. It is our belief that both the CD34+
cell and the OEC population are transiently lost in
nonproliferative diabetic retinopathy (NPDR) but, when
this population reappears, it does so as a more aggressive
and proliferative phenotype and upon reappearance, triggers
the angiogenic switch in proliferative diabetic retinopathy
(PDR). The eEPC population never disappears entirely but
rather shifts in its level of activity, sometimes being more
inflammatory than other times; thus its phenotype also
changes with the severity of retinopathy, being more
inflammatory in PDR and less in NPDR. Moreover, it has
been shown by Yoon et al. that early and late outgrowth
EPCs can act together to stimulate vascular repair [25].
Identification of EPCs based on FACS or magnetic
bead selection
In contrast to differential culture, many groups including
ours, have characterized endothelial precursors using a
panel of immunological and non-immunological markers in
freshly isolated cells and used these sorted cells directly for
either in vitro or in vivo studies. This is the approach
commonly used for the isolation of cells (from a patient’s
own BM or PB) for therapeutic use. The original
combination of CD34 and VEGFR-2 remains the most
common, but several other markers have been used to
refine the identification of this therapeutic cell type. Some
Fig. 1 Adult stem cells of the
bone marrow. The bone marrow
hosts at least two known types
of adult stem cells, the
mesenchymal stem cells
(MSC) and the hematopoietic
stem cells (HSC); the most
prominent adult stem cell in the
bone marrow. The HSC can
give rise to the hematopoietic
progenitor cells (HPC) which in
turn give rise to the lymphoid
progenitor cell, the myeloid
progenitor cells, and likely the
EPC. The precise origin of the
EPC is under debate as this cell
may directly arise from the HSC
or from the HPC. The bone
marrow microenvironment is
composed of bone marrow
stromal cells (which are the
source of SDF-1), adipocytes,
and cells of the bone matrix,
osteoblasts and osteoclasts. The
vessels within the bone marrow,
composed of pericytes and
endothelium, function to
provide a barrier between the
hematopoietic compartment
and the circulatory system.
Figure adapted from
Domen, et al. [5]
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have described CD133 (prominin) as an additional marker
[26] particularly to identify immature EPCs.
BM-derived CD14+ monocytes also demonstrate potential
to differentiate into endothelial cells [18]. Interestingly,
although several independent groups have shown a clear
development of an endothelial phenotype after selective
culture, many also found that the expression of monocytic
antigens persisted [18, 27]. Several additional studies
confirmed the overlap between EC andmonocyte phenotypes,
suggesting that using traditional EC markers such as acLDL
uptake, Ulex binding, CD31, CD105 (endoglin), CD144
(vascular endothelial cadherin), VEGFR-2, CD34 and Tie-2
may not be enough to distinguish between ECs andmonocytes,
and thus may not specifically identify EPCs [28–30]. Similarly,
Harraz et al. showed that cultured CD34−CD14+ PB-MNCs
express Tie-2, VEGFR-2, CD144, von Willebrand factor
(vWF), CD146, CD105 and eNOS [27]. Interestingly, another
report suggested that monocytes (CD14+), which express low
levels of CD34 (undetectable with conventional techniques),
may in fact contain the true progenitor cell population, with
the greatest regenerative capacity [31]. Considering the uncer-
tainty as to the most reliable method to identify circulating EPCs,
several studies have employed CD34/VEGFR-2 or CD34/
CD133 double positivity to quantify circulating EPCs and to
correlate their concentration to clinical conditions [32, 33]. This
is the strategy that we have used for most of our studies.
The failure to reliably characterize endothelial progeni-
tors has generated some skepticism and confusion within
the field of regenerative medicine. However, a study by
Loomans et al. [34] and an excellent review by Schatteman
et al. [8] have suggested that despite phenotypic overlap
between various BM-derived or circulating cell types, the
endothelial phenotype can best be characterized by three
features: eNOS expression, integration into tube-like
structures formed by human umbilical vein ECs
(HUVECs), and stimulation of tube formation by HUVECs.
It is suggested that these criteria might be the best in vitro
method of judging the endothelial phenotype, regardless of
the presence or absence of particular cell surface antigens.
This simplified interpretation is important, as it acknowledges
Fig. 2 Mobilization and homing are two closely related processes.
Mobilization involves the exodus of HSC/HPC from the bone marrow
into the circulation while homing is the “opposite” of this event. HSC
mobilize from the endosteal niche, move to the vascular niche, and
ultimately into the circulation. This normally occurs when stress
induces changes of SDF-1 levels in the bone marrow. The mechanism
of stress-induced mobilization as occurs following irradiation or
G-CSF-induced mobilization is not fully known, but is, in part,
accomplished by the upregulation of proteases such as MMP-2, MMP-
9, cathepsin-G and elastase. These proteases cleave niche retention
signals like membrane-bound stem cell factor (mSCF), SDF-1,
VCAM-1 and osteopontin (Opn). Gradients of fibroblast growth
factor 4 (FGF-4) also regulate mobilization. For homing events, key
steps are needed. Upon reaching the bone marrow vasculature, SDF-1-
stimulated circulating HSC/HPC express integrins such as very late
antigen 4 (VLA-4) and hyaluronan binding–cellular adhesion mole-
cule (CD44). These integrins, in turn, interact with vascular cell
adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1
(ICAM-1), E-and P-selectins expressed on bone marrow endothelial
cells which slows down the circulating HSC/HSP in a process known
as “rolling.” Following rolling, firm adhesion and subsequent
endothelia transmigration into the hematopoietic compartment is
mainly accomplished by VLA-4 interactions. Once extravasated the
cells, the cells migrate along extravascular hematopoietic cords toward
specific niches through as SDF-1 gradient or receding oxygen gradient
originating from the supporting osteoblastic or endothelia niches.
BMEC: Bone marrow microvascular endothelial cell. Figure adapted
from Wilson and Trumpp [10]
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the limitation of surface markers and affirms the importance of
the identification of EPCs according to their potential to
acquire functional properties of ECs.
The importance of progenitor characterization
to the pathogenesis of DR
Our working hypothesis is that populations such as freshly
isolated CD14+ cells and eEPCs are responsible for
“provisional repair,” that is, transient repair preparing the
environment for a more durable repair, which we believe is
the function of the CD34+ cell and the OECs. In healthy
retina both populations are participating in a temporal
manner with CD14+ cells and eEPCs homing in first,
attracting the CD34+ cells and OECs later. In NPDR, eEPCs
(and CD14+ cells) have reduced function as they cannot
recruit OEC (and CD34+ cells) into the retina to repair the
acellular capillaries, while in PDR the eEPCs take on a pro-
inflammatory phenotype and recruit too many OECs leading
to pathological neovascularization. This distinction may be
critically important to the derivation of cellular therapies. It is
our contention that for durable repair and sustained correction
of retinal ischemia the use of cells that are expanded in vitro
(eEPCs and OECs) may be better than freshly isolated cells.
Moreover, this extended ex vivo period allows more time for
correction of diabetes-induced dysfunction, which is described
below. How does the cell type that we have spent a decade
characterizing in DR, that is the CD34+ VEGFR-2+ EPC, fit
into all this? The origin of the OEC is from a CD34+
VEGFR-2+ population found in the circulation [6, 25, 35].
Diabetic EPCs are dysfunctional
In diabetes BM-derived progenitors are dysfunctional, pro-
ducing fewer endothelial cells with reduced proliferative and
migratory potential [36]. Enhanced oxidative stress in
diabetes contributes to progenitor dysfunction [37]. Accu-
mulation of ROS increases cellular/replicative senescence in
these progenitors as does increased angiotensin II, oxidized
low-density lipoprotein (ox-LDL) and homocysteine. EPCs
of diabetic origin show a reduced ability to integrate into EC
tubes in vitro compared to EPCs of non-diabetic origin [38–
40]. Vascularization is depressed when EPCs from STZ
treated mice are injected into normal mice [41]. Recently,
we showed that activation of the HDL receptor is protective
to EPCs by increasing eNOS [42], whereas activation of
ox-LDL receptor down-regulates eNOS, supporting a key
role for NO in the function of progenitors [43].
Our group and others have evidence that the development
of acellular capillaries may be due to failed attempts at repair
of injured capillaries and persistence of ischemia. For the last
10 years, our group has focused on understanding the basic
mechanism responsible for the diabetes-associated defect in
EPC function. Correcting this defect may allow the use of a
diabetic patient’s own EPCs for repair of their injured retinal
and systemic vasculature. Specifically in the retina, correction
of this dysfunction could treat early and intermediate stages of
vasodegeneration to enhance vessel repair, reverse ischemia,
and prevent progression to the late stages of DR (Fig. 5).
However before EPCs can be used therapeutically in DR to
reendothelialize acellular capillaries and eliminate retinal
ischemia, several key questions must be answered. What
triggers this phenotypic change in diabetic cells taking them
from reparative to deleterious? What is the best reparative
BMDC population? Are some subpopulations more resistant
to the injurious effects of diabetes? Should the BM be a target
for DR therapy?
Fig. 3 Common methods of precursor isolation. Culture of eEPCs
includes a 5-day process wherein non-adherent MNCs give rise to the
EPC colony. OECs are derived from adherent MNCs cultured on
collagen for 21 days in endothelial growth conditions and demonstrate
typical cobblestone morphology
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Nitric oxide (NO) in the pathogenesis of DR
NO generation arises from the guanidino group of L-
arginine and is a NADPH-dependent reaction catalyzed by
a family of NOS. Three distinct isoforms of NOS,
consisting of endothelial NOS (eNOS), neuronal NOS
(nNOS), and inducible NOS (iNOS) are similar in structure
and function, utilizing L-arginine, oxygen and NADPH as
substrates, and requiring FAD, FMN, calmodulin, and
tetrahydrobiopterin as co-factors. The catalytic mechanism
of NOS involves flavin-mediated electron transport from
NADPH to the terminal heme, where oxygen is bound and
incorporated into NO and citrulline [44]. Maintaining an
adequate cellular supply of L-arginine is critical for normal
Fig. 4 Morphology of Early
and Late Outgrowth EPCs. (A)
Typical colony of early EPCs
which develop into spindle
shaped cells by day 7 (B). Early
EPCs do not proliferate readily,
which leads to the typical sub-
confluent appearance. In
contrast, late outgrowth ECs (C)
show rapid growth as
indicated by the dividing




Fig. 5 Schematic of the hypothetic diabetic retinopathy progress. In
physiological conditions, CD34+ EPCs contribute to routine blood
vessel maintenance through eNOS activation and NO-mediated
stimulation of CD14+ EPCs. In diabetes, initially, cytokines like stem
cell factor (SCF), monocyte chemoattractant protein-1 (MCP-1),
interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-α) released
by dysfunctional CD34+ EPCs initiate CD14+ EPC-mediated aberrant
vascular repair resulting in retinal ischemia. This phase is referred to
as non proliferative diabetic retinopathy (NPDR). The vasodegener-
ative phase of diabetic retinopathy associated with reduced reparative
function of EPCs evolves in the proliferative diabetic retinopathy
(PDR). This phase is characterized by pathological neovascularization
seen in the diabetic retina
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vascular function. Deficiencies in L-arginine supply have
been strongly implicated in vascular diseases, including
diabetes [45]. If the supply of L-arginine or any cofactor does
not meet the needs of active NOS, NOS becomes “uncoupled”
and uses molecular oxygen as a substrate to form O2− instead
of NO. An imbalance between L-arginine availability and
NOS activity can occur when cellular transport of L-arginine
is inhibited [46] or when there is reduced recycling of
L-citrulline back to L-arginine, or when an elevated
catabolism of L-arginine by arginase exists [47, 48].
We demonstrated in a spontaneous rat model of type 2
diabetes that eNOS was decreased while NADH oxidase, a
major source of superoxide in the vascular endothelium, iNOS,
and ONOO− were all increased in the retinal vasculature [49].
The shift in redox state in diabetes with increased ROS
causes increased interaction of NO with O2−, resulting in loss
of bioavailable NO and formation of ONOO−. The reduced
NO and elevated ONOO− can lead to microvascular
dysfunction in diabetes [50–52]. ONOO− is a potent oxidant
that can attack many types of biological molecules; a high
level of ONOO− initiates lipid peroxidation, hydroperoxides,
nitration of amino acids such as tyrosine, oxidation of
antioxidants such as ascorbic acid and α-tocopherol, and
direct DNA damage. The increased oxidative stress associat-
ed with diabetes can limit tetrahydrobiopterin availability.
Moreover, ONOO− formation affects tetrahydrobiopterin
interaction with NOS [53], leading to this “switch” or
uncoupling of NOS from producing NO to producing O2−.
Advanced glycation end products (AGEs) seen in the diabetic
individuals can also directly react with NO, diminishing NO
bioavailability both in vitro and in vivo [54].
In type 1 diabetes, uncoupled eNOS was found to be the
major source of ROS generation and, when blocked, there
was reduced retinal leukostasis, blood retinal breakdown
and reduced retinopathy [55]. Whereas nNOS is highly
expressed in the retina, its role in DR is still being
determined. Interestingly, nNOS knock-out mice still
develop retinal leukostasis and blood retinal barrier break-
down suggesting that iNOS or eNOS may have a more
central role in these particular aspects of DR. In a model of
diabetic ketoacidosis, in which acetone is administered to a
mouse, tissue damage is mediated by free radical generation
via iNOS overexpression [56]. Diabetes-induced vascular
dysfunction in rats was prevented by administration of a
specific inhibitor of iNOS, 1400W [57, 58].
Is reduced bioavailable NO responsible
for the endothelial progenitor dysfunction observed
in DR?
NO-mediated signaling pathways are essential for EPC
mobilization from the BM [59–61]. NO activates MMP-9,
releasing soluble Kit ligand, which shifts EPCs and
hematopoietic stem cells (HSCs) from a quiescent to a
proliferative niche and stimulates rapid cell mobilization to
the PB [60, 62]. NO regulates migration of EPCs into
ischemic sites [59, 63–65] and their survival [66]. We and
others have shown that diabetic EPCs have decreased eNOS
activity; more importantly that exogenous NO can correct the
migratory defect in these cells (Fig. 6) [67, 68]. The impaired
in vivo re-endothelialization capacity of human diabetic
EPCs was restored by small interfering RNA silencing of
NAD(P)H oxidase subunit p47(phox) [64]. Oxidative stress
impairs in vivo reendothelialization capacity of endothelial
progenitor cells [69]. We show in the preliminary data that
pretreatment of diabetic CD34+VEGFR-2+ EPCs with apoc-
ynin or gp91ds-tat decreased superoxide production and
increased NO availability. Pretreatment with apocynin or
gp91ds-tat reversed the impaired migration of diabetic EPCs
in response to SDF-1 and VEGF in vitro and enhanced their
integration into ischemic retinal vasculature in vivo [70].
Propofol, a peroxynitrite scavenger, inhibits NF-kB activation,
increases NO production and protects EPCs from apoptosis
Fig. 6 Release of EPCs is reduced in a diabetic environment. In a
non-diabetic environment ischemic injury results in the release of
growth factors at the site of injury which stimulate the release of EPCs
from bone marrow. EPCs then migrate to the site of injury and initiate
blood vessel repair (angiogenesis). In a diabetic environment ROS,
proinflamatory and antiangiogenic factors are increased above non-
diabetic levels while NO is reduced. This results in a blunted response
to ischemic injury and marginal repair at the site of injury
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[38, 71, 72]. High glucose enhances EPC senescence, impairs
migration and tube formation. These effects can be ameliorated
by co-incubation with the NO donor sodium nitroprusside and
worsened by eNOS inhibition [73]. Diabetic EPC dysfunction
was improved by the eNOS activator AVE 9488 and with
PPARγ-agonists [74, 75]. Specifically, these agonists promote
differentiation, increase EPC number and migratory activity,
and reduce EPC apoptotic rate [76]. Decreased NO can be
due to increased oxidative degradation as well as reduced
synthesis. ADMA, an analogue of the amino acid L-arginine,
inhibits the formation of NO and augments vascular oxidative
stress, partly via eNOS uncoupling, resulting in higher
superoxide radical generation. ADMA levels are increased
in diabetes [76] and ADMA represses EPC proliferation,
differentiation, and function, in a concentration-dependent
manner [77]. The enzyme dimethylarginine dimethylamino-
hydrolase (DDAH) inactivates ADMA and regulates NO
production [78]. Overexpression of DDAH in vitro and in
vivo increased NO production [79].
BM microenvironment is dysfunctional in diabetes
The BM stem cell niche is a specialized microenvironment
that nurtures and regulates the stem cell pool. We showed
that diabetic BM has large amounts of fat compared to BM
from healthy controls [80]. Adipocyte-rich marrow harbors
a decreased number of progenitors and relatively quiescent
stem cells. Mice that are genetically deficient in adipogenesis
show accelerated hematopoietic recovery after BM ablation, a
phenomenon that can be reproduced pharmacologically in
wild-type mice through PPAR-γ inhibition [81]. These results
suggest a novel therapeutic approach to enhance hematopoietic
engraftment after marrow or cord blood transplantation, or to
ameliorate aplasia in genetic BM failure syndromes. Further-
more, this is a mechanism for the myelosuppression observed
in patients treated with the PPAR-γ agonist rosiglitazone [82–
84], a diabetes drug known to increase marrow adiposity [85].
BM adipocytes have a primarily suppressive effect on
hematopoiesis within the BM microenvironment. BM adipo-
cytes are less supportive of hematopoiesis in vitro than their
undifferentiated stromal or pre-adipocytic counterparts, in
part due to reduced production of growth factors such as
granulocyte-macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony-stimulating factor (G-CSF)
[86, 87]. Moreover, adipose tissue secretes neuropillin-1
[88], lipocalin [89, 90], adiponectin [91] and TNF-α [92],
each of which can impair hematopoietic proliferation. Of
note, TNF-α and adiponectin inhibit progenitor activity [25,
92, 93] suggesting that adipocytes prevent hematopoietic
progenitor expansion. Adipocytes and osteoblasts originate
from mesenchymal stem cells within the BM, where both
compartments hold a reciprocal relationship [93]. Balancing
the supportive role of the osteoblast in the HSC niche, our
and others’ data implicate adipocytes as negative regulators
of hematopoiesis and that the diabetic fatty marrow has a
deleterious effect on EPC function.
Thus, based on these observations, we conclude that
both freshly isolated and expanded EPCs can potentially be
used for restoration of injured retinal vasculature and that
this ultimately will lead to correction of retinal ischemia by
restoring proper blood flow to the retina. Whether CD34+
cells, angiogenic monocytes, such as CD14+ cells, eEPCs
or OECs represent the cell population with the greatest
therapeutic utility is currently unknown and if there are
unique characteristics of the retinal vasculature that make
one of these populations better suited for repair is also
unknown. Only future studies will provide the needed
information of determining the most effective cell therapy
for diabetes induced vasodegenerative disease of the retina.
The CD14+ cells and the eEPC, we believe, are responsible
for “provisional repair,” that is transient repair preparing the
environment for more “durable repair,” which is the
function of the CD34+ cells and the OECs. In healthy
retina, both populations participate in an ordered, temporal
sequence with for example EPCs homing in first, attracting
the OECs later. However, in NPDR, eEPCs have reduced
function and cannot recruit OECs leading to ineffective
repair of damaged capillaries and the development of
acellular capillaries. Further complicating this situation,
we believe that OECs may be markedly reduced in numbers
in NPDR and may even be “transiently lost” from the
circulation; thus are not available for repair of acellular
capillaries either. Perhaps in PDR, OECs reappear as a
more aggressive and proliferative phenotype which triggers
the “angiogenic” switch and the onset of PDR or the eEPC
population is more aggressive too. Likely there exists a
shift in the level of activity of eEPCs as diabetic retinopathy
progresses, being more inflammatory in PDR (and less in
NPDR). In both populations, dysregulation of NOS is
central to these phenotypic transitions, which are further
influenced by the changing BM microenvironment associated
with diabetes. Ex vivo correction of the diabetes-induced
defects in these cells, or systemic modulation of the BM to
correct the dysfunction of these cells will reduce the
development of retinopathy. We showed that healthy but not
diabetic CD34+ cells attached and assimilated into the retinal
vasculature [15]. These studies show the potential of EPC
therapy for ischemic retinopathies but they also highlight the
need for a more thorough characterization of EPC subsets so
that the precise fate and utility of delivered cells can be
determined without the potential to evoke unwanted
responses. This is especially important in the context of a
complex milieu such as diabetes which is known to alter
EPC phenotype. For example, Sca-1+ bone marrow-derived
EPCs transplanted into diabetic mice convert to a pro-
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inflammatory and anti-angiogenic phenotype and exacerbate
limb ischemia [94]. Therefore, transplanting the wrong cell
type into the diabetic retina could enhance differentiation
could potentially promote switch to proliferative retinopathy
EPC in ocular angiogenesis
Retinopathy is the most common diabetic complication
with almost all diabetic patients developing background
retinopathy [95]. Both type 1 and type 2 diabetes is
associated with widespread EPC dysfunction [96]. Several
studies have shown that circulating EPC number is reduced
in patients with NPDR [97] but increased in patients with
PDR [98]. These observations were confirmed by Brunner
et al. who conducted a case-control study that compared 90
patients with type 1 diabetes with and without retinopathy.
They also demonstrated that in type 1 patients with
retinopathy, EPCs underwent stage-related regulation. In
NPDR, a reduction of EPCs was observed, while in
proliferative retinopathy, a dramatic increase of mature
EPCs was observed [99]. These findings are consistent with
the hypothesis that the vasodegenerative phase of diabetic
retinopathy is associated with reduced reparative function
of EPCs and that in PDR these cells may be responsible for
the pathological neovascularization seen in the diabetic retina.
Astrocytes, as mentioned earlier, are known to play a
pivotal role in the normal developmental retinal vasculariza-
tion. Otani et al. showed that intravitreally injected Lin– BM
cells selectively target retinal astrocytes, cells that serve as a
template for both developmental and injury-associated retinal
angiogenesis. When Lin– HSCs were injected into neonatal
mouse eyes, they participated in normal developmental
angiogenesis. When EPC-enriched HSCs were injected into
the eyes of neonatal rd/rd mice, whose vasculature ordinarily
degenerates with age, they prevented the retinal vascular
degeneration and this vascular rescue was associated with
neuronal rescue [100]. Normal developmental vessels and
exogenous progenitor cell targeting to astrocytes and the
normal vascular plexus were both found to be dependent on
the functional adhesion of R-cadherin as confirmed by
disruption of HSCs targeting to the three distinct retinal
vascular plexuses following R-cadherin blockade [101].
The role of glial cells during pathological retinal
neovascularization is still under investigation. Loss of
astrocytes and microglia directly correlates with the
development of pathological NV in a mouse model of
oxygen-induced retinopathy (OIR). These two distinct glial
cell populations were found to have cooperative survival
effects in vitro and in vivo. The intravitreal injection of
myeloid progenitor cells, astrocytes, or astrocyte-
conditioned media rescued endogenous astrocytes from
degeneration that normally occurs within the hypoxic, vaso-
obliterated retina following return to normoxia. Protection
of the retinal astrocytes and microglia was directly
correlated with accelerated revascularization of the normal
retinal plexuses and reduction of pathological intravitreal
neovascularization normally associated with OIR. Using
astrocyte-conditioned media, several factors were identified
that may contribute to the observed astrocytic protection
and subsequent normalization of the retinal vasculature,
including vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (bFGF). Injection of VEGF or
bFGF at specific doses rescued the retinas from developing
OIR-associated pathology, an effect that was also preceded
by protection of endogenous glia from hypoxia-induced
degeneration. These data suggest that vascular-associated
glia are also required for normalized revascularization of the
hypoxic retina and protecting glial cells may provide a novel
strategy by which normalized revascularization can be
promoted and the consequences of abnormal neovasculariza-
tion in retinal vascular diseases can be prevented [102].
Another condition associated with pathological angiogensis
is age related macular degeneration.
Csaky’s group demonstrated that EPCs, in the form of
OECs can be isolated expanded successfully from the
peripheral blood of elderly control and AMD-affected patients
and demonstrated significantly higher number of initial OEC
clusters and expansion potential of OECs in patients at risk for
or already affected by nvAMD. The group postulated that
OECs may be used for further phenotypic, genetic, and
functional analyses in patients with nvAMD [103].
Proliferative sickle cell retinopathy (PSR) is an uncommon
complication in individuals with sickle cell trait, also called
AS hemoglobinopathy (HAS), occurring more frequently in
patients with SC hemoglobinopathy, S-thalassemia and SS
hemoglobinopathy [104]. Interestingly, KDR+/CD34+/
Cd45dim cells were found to significantly higher during
painful crisis [105], suggesting that patients during sickle
crisis may be more at risk for development of ocular
neovascularization.
Conclusion
Even though EPCs constitute a relatively small percentage
of circulating cells, they can specifically and effectively
home to sites of injury including the retina. Based on the
promising results of the REPAIR-AMI trial [106], introduc-
tion of non-diabetic EPCs into diabetic patients is being
considered to promote wound healing which could guide
their use for future treatment of diabetics with extensive
retinal or macular ischemia. What exactly is the promise of
cellular therapy for diabetic retinopathy? While peripheral
blood or bone marrow CD34+ cells show promise, we
believe that the ex vivo expanded eEPCs and OECs may
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equally represent cell populations with great therapeutic
utility and may provide the basis for an effective cell therapy
for vasodegenerative disease in the retina. One population of
cells may be responsible for “provisional repair,” i.e.
transient repair, preparing the environment for more durable
repair, which is the function of another EPC population. In
healthy retina both populations participate in an ordered,
temporal sequence. In NPDR, EPC populations have reduced
function as they cannot be recruited into the retina to repair
the acellular capillaries, while in PDR the EPCs may take on
a pro-inflammatory, proangiogenic phenotype and perhaps
too many EPCs lead to pathological neovascularization.
While this hypothesis remains to be proven, the concept of
identifying the “best” reparative cell and the ideal time for its
administration is critically important to the derivation of
cellular therapies. In diabetes, dysregulation of NO is central
to phenotypic transitions of these EPC to cells with reduced
reparative function and this cellular change may be further
influenced by the shifting bone marrow microenvironment
associated with diabetes. Ex vivo correction of the diabetes-
induced defects in these cells prior to administration to the
patient or systemic modulation of the bone marrow to correct
the dysfunction of these cells will likely be new strategies for
the future to prevent as well as treat diabetic retinopathy.
Future perspective
The controversy surrounding EPCs will remain an area of
active debate and rigorous investigation. The questions
remain, what is the source of the vascular reparative cell? Is
it the bone marrow or is it the endothelium itself? The field
is replete with inconsistencies that have resulted in some
disagreement and in differences in terminology used by
different groups, such as “endothelial—like cells,” instead
of endothelial cells, because the precursors express the
leukocyte marker CD45. Others justify the outgrowth cells
as bona fide products of EPCs based on the observation that
the input cells did not express CD45.
It is our feeling that we may be dealing with the same
EPCs and that all this disagreement is counterproductive.
The EPC may transition through many stages (phases) and
may represent the same cell with different phenotypes
depending on the isolation conditions or the culture
conditions, as it is well established that a little VEGF in
the culture medium goes a long way to making the cell
appear “endothelial-like” and may explain, in part, the
“appearance” of the OEC. Another hurdle is that some
investigators find that this “elusive precursor” expresses the
hematopoietic marker CD45 while others vehemently argue
that it doesn’t. The next big question is the therapeutic
potential of the EPC. However, since the community can’t
agree on the actual cell, optimization of its use therapeu-
tically will likely be problematic. Careful assessment of the
putative cell in vivo will be needed following in vitro
characterization.
Key issues
& It has been a decade since EPCs were discovered but
considerable debate remains about the phenotypic
nature and cellular derivation of these cells. Defining a
correct population of EPC is of salient importance for
their therapeutic use.
& Pharmacological manipulation of EPCs will be necessary
to correct diabetes associated defects.
& Before clinical use of EPCs, it will be necessary to titrate
their dosing regimen to avoid unwanted responses such as
accelerated proliferative retinopathy or, perhaps even the
initiation of a malignancy.
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